Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions

Mikhail Shugay1, Iñigo Ortiz de Mendíbil, José L Vizmanos

  • 1Department of Genetics, University of Navarra. 31008 Pamplona, Spain.

Abstract

Insights

Oncofuse is a new computational tool that predicts the cancer-driving potential of gene fusions identified through next-generation sequencing. This helps researchers prioritize which fusions to study further for cancer therapy development.

Area of Science:

  • Genomics
  • Bioinformatics
  • Cancer Research

Background:

  • Chromosomal aberrations lead to gene fusions, a significant cause of cancer.
  • Identifying oncogenic gene fusions is challenging, especially in carcinomas, due to genomic complexity.
  • Next-generation sequencing (NGS) detects numerous fusion transcripts, necessitating methods to distinguish driver from passenger fusions.

Purpose of the Study:

  • To develop a computational pipeline, Oncofuse, for classifying gene fusion sequences based on their oncogenic potential.
  • To differentiate between 'driver' fusion sequences with oncogenic activity and 'passenger' sequences.

Main Methods:

  • Developed Oncofuse, a naive Bayes Network Classifier.
  • Utilized genomic hallmarks of known oncogenic fusion genes for training and testing.
  • Implemented the pipeline using a Java/Groovy script.

Main Results:

  • Oncofuse accurately predicts the oncogenic potential of novel gene fusions.
  • The pipeline demonstrated robust performance with good precision and recall rates in cross-validation and independent tests.
  • Identified key features of oncogenic fusions to calculate their driver probability.

Conclusions:

  • Oncofuse is a valuable tool for prioritizing experimental validation of novel fusion sequences from cancer transcriptomes.
  • Facilitates the identification of therapeutically relevant gene fusions detected by NGS.
  • Aids in understanding the genomic landscape of cancer by distinguishing driver events.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...